Alessandro Gronchi, MD
Chair Sarcoma Service – Department of Surgery
Fondazione IRCCS Istituto Nazionale dei Tumori (National Cancer Institute)
Alessandro Gronchi MD received his MD degree from Milan University in 1992, completed his residency training in General Surgery in 1997 and a fellowship in Surgical Oncology in 1998. He holds the National Scientific qualification for full professor of General Surgery. He is chair of the Sarcoma Service at the National Cancer Institute – Milan – Italy since 2001.
He runs the institutional Sarcoma Data Base, which gathers information on over 10000 patients affected by soft tissue sarcoma (STS), desmoid-fibromatosis (DF) and GIST, treated over the past 3 decades in Milan. He is involved in all institutional research activities on sarcoma, which include neoadjuvant therapies in extremity and retroperitoneal sarcomas, new targets for specific STS types, genomic characterization of DF and mechanisms of resistance to therapy in GIST. He is the Principal Investigator of several Italian and International trials on STS, DF and GIST.
He serves as member of the board of directors of the Italian Sarcoma Group, member of the board of directors of the European Society of Surgical Oncology 2020-2022; international representative on the executive council of the SSO 2021-2024; member of the Sarcoma Task Force of the European Society for Medical Oncology. He was chair of the EORTC Soft Tissue and Bone Sarcoma Group (2015-2017), president of the Connective Tissue Oncology Society (2016); president of the Italian Society of Surgical Oncology (2019-2021). He is member of the European Surgical Association, the American Society of Clinical Oncology and honorary member of the Polish Society of Surgical Oncology. He is one of the initiators of a global collaborative effort on retroperitoneal sarcoma (Trans-atlantic Australasian RetroPeritoneal Sarcoma Working Group, TARPSWG), which involves over 150 institutions worldwide. Dr. Gronchi has authored more than 460 scientific publications (Scopus HIndex 83), serves as Associate Editor of Annals of Surgical Oncology, Journal of Surgical Oncology, Critical Reviews in Oncology/Hematology, Tumori Journal, Sarcoma Journal.
A medical oncologist, Silvia Stacchiotti has a life-time professional dedication to patient care and research in bone and soft tissue sarcoma (STS), and gastrointestinal stromal tumor (GIST).
She works in the Adult Mesenchymal and Rare Tumor Medical Treatment Unit, Cancer Medicine Department. at the Fondazione IRCCS Istituto Nazionale Tumori (Milan, Italy) where she is involved in all institutional research activities on sarcoma, with a special focus on ultra-rare sarcomas.
Her work focuses on the identification of new treatments and treatment modalities for adult patients affected by sarcomas. As sarcomas are rare tumors and the sarcoma family comprises >80 different histologies, over the last 20 years she has been working in collaboration with the Institutional groups and the international sarcoma community and patient advocates to improve cure and care of selected sarcoma types through the 1) description of the natural history and sensitivity to conventional agents available for treatment of sarcoma; 2) identification of new targets, mechanisms of resistance and anticancer agents, 3) design of prospective clinical trials, 4) coordination of consensus meetings with the community of experts to draft clinical guidelines on the best approach to each sarcoma type; 5) interaction with the regulators (FDA; EMA) to help the approval of new drugs for sarcoma patients; 6) build prospective registries / observational studies.
She is the current president of the Italian Sarcoma Group (ISG), the Italian scientific society for research and care of all ages sarcoma patients, and the current treasurer of the Connective Tissue Oncology Society (CTOS), the international scientific society for sarcomas.
She is the faculty coordinator of the Sarcoma group of the European Society for Medical Oncology (ESMO) and the subject editor of the ESMO guidelines committee for sarcoma and GIST. She is the chair of the systemic therapy subcommittee of the EORTC Soft Tissue and Bone Sarcoma Group. She is member of the advisory boards of Alleanza Contro il Cancro (ACC) and of the Federazione Italiana Gruppi Cooperativi (FICOG).
She collaborates with several sarcoma Patient Advocacy Groups (PAG), among which the Chordoma Foundation, the Epithelioid Haemangioendothelioma (EHE) Rare Cancer Charity UK (EHERCC) the EHE Foundation US, the Desmoid Tumor Research Foundation, the Leiomyosarcoma Foundation, in which she serves as a member of the corresponding medical advisory boards.
She is the Principal Investigator of several trials on sarcoma. She has authored >220 scientific publications (H Index 55).
Born in 1968, Silvia Stacchiotti received her medical degree in 1993, in Milan, and trained at INT. She is certified in Clinical Oncology. She has four children.
Peter Ferguson is an orthopaedic oncologist and the Albert and Temmy Latner Professor and Chair of Orthopaedic Surgery at University of Toronto. He is the head of the largest sarcoma site group in Canada at Mount Sinai and Princess Margaret Hospital's, and the past President of the Canadian Orthopaedic Oncology Society.
He has won numerous teaching awards including the Robert Salter Award from the Division of Orthopaedic Surgery, the Bruce Tovee Undergraduate and Postgraduate Awards from the Department of Surgery, the WT Aikins Award from the Faculty of Medicine, twice the Award for Excellence in Postgraduate Medical Education at the University of Toronto and the AMS Donald Richards Wilson Award by the Royal College of Physicians and Surgeons of Canada.
He has authored over 170 publications in clinical outcomes of patients with sarcoma, surgical education and translational research in radiation effects on bone and soft tissue healing.